Hims & Hers Health, Inc. (HIMS) Earnings Call Transcript
November 9, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for joining the Hims & Hers Health earnings call for the third quarter of 2026. Joining me today are Andrew Dudum, our Co-Founder and Chief Executive Officer; Yemi Okupe, our Chief Financial Officer; and Mo ElShenawy, our Chief Technology Officer. Before Andrew takes over, I want to go over the legal safe harbor and our cautionary declarations. Some of the statements and projections about future results in this presentation are forward-looking statements. They rest on, among other things, how we currently see the market, competitors, and regulatory expectations, and they carry risks and uncertainties that might make actual results differ materially. We are under no obligation to update any forward-looking statement publicly after today's call, whether because of new information, future events, changes in assumptions, or anything else. The risks, uncertainties, and other factors that might cause actual results to differ from our forward-looking statements are covered in our earnings release and SEC filings. For a discussion of these risk factors as they relate to forward-looking statements, please see our recent earnings release and our most recently filed 10-K and 10-Q reports. Today's presentation also includes certain non-GAAP financial measures. We point you to the reconciliation tables to the most directly comparable GAAP financial measures included in today's press release. That information, along with a link to today's webcast, is available at investors.hims.com. After the call, the webcast will be archived on the website for 12 months. With that, I'll hand the call over to Andrew.
Thank you, Bill. Good afternoon, everyone, and I appreciate you being here with us. This quarter represented genuine advancement in our effort to create a company unlike any that we believe has existed until now: a digital health platform for everyday use that tens of millions of people depend on — not just for one treatment, but for every aspect of how they look after themselves. Before we get into the quarter, I'd like to take a few minutes to discuss the thesis underlying all of what we're building, since it clarifies both the results you're seeing today and the choices we're making for the years to come. Our belief is straightforward: within healthcare, the winner is whoever holds the customer relationship; saying that is easy, while accomplishing it is extremely difficult. The majority of companies in our sector organize themselves around a treatment, a condition, or a moment in time. They capture one transaction, but then they lose the connection. What customers want is different. They want somewhere that understands them, remains with them, and expands alongside them as their needs evolve. That is the place we are building — a single platform that unites the finest clinical expertise, diagnostics, prescription medications, daily insights from wearables, supplements, and additional tools supporting the way someone lives each day. What enables this is a business model that we believe is unmatched in healthcare. We hold brands that customers trust. We hold the platform linking customers to care; we hold over 1 million square feet of pharmacy, lab, and compounding infrastructure that delivers that care. We hold the AI technology tying everything together into one uninterrupted, continuous thread. Since our relationship is direct with the customer, each improvement we make within one specialty reinforces every other one, and each efficiency we unlock across our infrastructure can be given back to the customer through a lower price or more comprehensive care; that is a multiplier model rather than a transactional one, and it's why we believe value in this industry will accumulate to us and our ecosystem partners as time goes on. The foundation is substantial already. Revenue growth sped up to nearly 50% during this quarter. Close to 3 million people on four continents depend on us for access to care. That trust has turned us into a valuable partner for global pharmaceutical leaders such as Novo and Lilly, and it puts us in position to continue delivering the most innovative treatments to our customers as those treatments reach the market; we've also welcomed Andrew Huberman, the world-renowned neuroscientist and tenured Stanford professor, onto our board and as a scientific and brand marketing advisor. Our own pharmacy and lab infrastructure keeps scaling, generating efficiency throughout every specialty. Combined with an AI-native experience capable of supporting customers at all hours, that infrastructure puts us in position to launch treatments of growing complexity, among them testosterone replacement therapy this quarter and our Peptides Plus offering later this month. Our long-term strategy follows directly from this thesis, and it depends on three critical commitments. First, win metabolic health in the US and around the world. Second, lead the major markets globally. Third, stay at the leading edge of category expansion, so the platform keeps widening what it can offer the people who rely on it. Each of these strengthens the others, and taken together they capture how Hims & Hers turns into the worldwide home for consumer health. We are putting aggressive investment behind all three, since this opportunity is expanding fast and we think it will be worth more with each passing quarter. Every choice we made during this quarter supported those commitments, including the way and the timing of deploying our marketing dollars. Over the last few quarters, the weight loss business has gone through structural shifts, and we have deliberately reduced marketing spend so we can accomplish three things before the new year arrives. The first was to put ourselves in position to win in the metabolic business. That means collaborating with Lilly so we can deliver a seamless experience across a complete assortment of weight loss medicines. It means collaborating closely with Novo on broadening assortment and pricing options while getting ready to launch CagriSema as soon as it becomes available; it means creating innovative multi-month subscriptions that make it simpler for customers to obtain medications at price points that are easier to reach. The second was getting ready to invest aggressively across our international markets. In key regions such as the UK, Germany, and Australia, we are bringing our brands together under Hims & Hers, and we will redeploy marketing investment together with pricing actions meant to capture share in markets where we see substantial revenue potential. The third was to build the flexibility to invest behind the new specialties and offerings we are adding to the platform, both in the capabilities required to deliver them and in raising awareness so customers know these are available as we head into 2027. Each of these choices sacrifices near-term subscriber growth in exchange for a stronger position in the years ahead. That is a trade we will make every time, and we will deploy our next wave of marketing investment before the new year, when interest in weight loss hits its yearly peak and when the broader assortment, the more connected care experience, and the greater capacity to serve the full range of our customers' needs are all in place. Let me address each commitment in turn. Metabolic health comes first for a reason. It is the entry point. It is where people most often look for help initially, and once we earn a strong, trusted relationship there, we earn the right to care for them in other areas that matter to them; that is what makes it the foundation of the customer relationship instead of merely our largest category. It is also among the biggest markets in healthcare, and we think we are still in the very earliest days of adoption. It is also a highly profitable business over the long term, and we need not speculate about that. Our international markets are ahead of the US when it comes to the arrival of lower prices and generics, and they reveal to us where this category is headed. Our international teams bring years of experience collaborating with Novo and Lilly, and the trend holds steady: when prices decline and more treatment choices become available, additional customers join the platform, remain with us longer, and our margins get stronger. As categories mature, economics frequently get better, and we're building the US business with that in mind. It's the same cycle we've witnessed in sexual health and hair. Maturation draws more people into care, and our platform's strength lies in customers being able to access all of it in one place, with a care team that helps them find what's right for them. In the US, our collaboration with Novo reignited growth in our weight loss specialty. We're now deepening that partnership and plan to expand assortment and pricing options so it's easier for customers to start and stick with their treatment; we're also preparing for the launch of CagriSema once available. Through our recently announced agreement, we'll expand access to Lilly's GLP-1 medications Zepbound and Foundayo, offering customers a seamless experience across the full assortment of their weight loss medicines.
We're truly thrilled to be teaming up with Lilly in this new capacity, and we're eager to keep collaborating with them for the good of patients. In addition, with the new year coming soon, we're preparing to launch flexible subscriptions covering multiple months across our full product range, which will make it easier for customers to stick with a treatment plan and work toward their health objectives at a cost that suits their budget; we'll continue to put partnerships first across the entire industry so that whenever an innovative therapy comes to market, our customers are able to obtain it here. That product range will be offered alongside an AI-native experience that will soon be available to virtually all of the weight loss customers on our platform. As Mo will explain, this journey is boosting involvement throughout the specialty—helping customers remain consistent with their treatment plans, handle side effects, and connect with a provider fast when adjustments are needed. Through that involvement, the initial touchpoint grows into a lasting relationship. The deeper our understanding of customers, the more value we can deliver. Our US achievements give us the assurance to pursue our second priority: taking the lead globally, where digital health is still developing as a trusted choice. We want Hims & Hers to be equated with consumer-centric healthcare—not just in the US, but across every major market worldwide. Overseas sales are expected to surpass an annualized $1 billion run rate during 2027, since clients in those regions are adopting a full digital health offering that, in our view, has not previously existed for them at home. For that reason, we are allocating additional capital to the UK, Germany, and Australia. In our view, these countries hold considerable revenue upside, and we plan to move decisively to build market leadership while the category remains in its formative stage. We do not think any competitor in these countries matches our mix of breadth, scale, infrastructure, and expertise. After completing the Eucalyptus deal in June, we have acted swiftly. Hers has launched in the UK and Australia, where it serves customers in hair, menopause, and weight loss, while Hims has debuted in Germany and Australia. Learning flows both ways. Our overseas markets are showing us how a wide metabolic range benefits customers, and we're bringing that insight into the US. The wide range of specialties behind our successful US approach is now reaching a worldwide customer base, which positions us to take the lead in each market we enter. Our third pledge is to remain at the leading edge of category growth, and that's where our platform spending is already delivering results. In our view, the platform is what lets us push further into complex care and act fast, and this quarter gave us two plain examples. We expanded our testosterone lineup to include injectable as well as oral TRT — the first product we've launched that involves controlled substances. That step was something we were ready for, since our testosterone expertise has become so thorough: blood draws done at home, monitoring across time, and provider-directed treatment that gets adjusted along the way. People using our testosterone service aren't just getting a wide range of prescriptions; they're getting them with a clinical team behind them, the insights needed to make informed choices, and the option to ask a question any time one comes up. That same preparedness is why we feel confident about launching Peptides Plus later this month, which will feature clinician-led treatment plans and access to routine blood testing. We intend to follow with TB-500 and BPC-157, compounded and manufactured in the US. Supporting each of these offerings is over a million square feet of pharmacy and lab facilities, extensive sterile compounding expertise, and clinical leadership guiding the design. Any complicated health condition that calls for continuous oversight and a stable group of caregivers fits this approach, and the list of areas we're able to support this way continues to grow. With our pharmacy and tech capabilities expanding, we become more productive in every specialty we handle, and our intention is to keep passing those gains along to customers—whether by charging less or by delivering broader care for the same cost. In either case, each new category strengthens what the platform offers the customer and makes it tougher for rivals to match. At the time we started this company, convenience of access was what drew people to us. Nowadays, people want a lot more: greater selection, stronger value, and a care team familiar with them that stays by their side through life's transitions. That's elevating expectations throughout healthcare, and it's exactly what we've been working toward from the start. The platform is what enables all of this. At present, our customers get a single care team in one thread, with care coaches, support, clinicians, and pharmacy functioning together as one unified system; that's what enabled the launch of TRT, what has us prepared for Peptides Plus, and what keeps improving the care experience for each customer. The shape of what care will become is beginning to come into view, and Mo and his team are nearer to it than anyone else. I'll now pass things to Mo, our CTO, so he can explain more about how this is affecting both our customers and our business.
Thanks, Andrew. It's good to be back and to give you a closer view of what our technology group accomplished this quarter. I'd like to describe our progress along three dimensions: how widely the AI-native experience now extends, how deeply it operates inside the care journey, and how fast the team can keep building on top of it. Each of those rests on one principle: we aren't creating an AI feature and bolting it onto a healthcare company. What we're creating is a platform whose foundation is AI, built to manage clinical complexity. The strongest evidence of that arrived with our first controlled substance launch. Delivering injectable and oral TRT onto the platform required embedding prescription workflows, compliance checks, and lab integrations right into the care flow, and it went live on the very same foundation that supports every other category; that's what taking a platform approach looks like in real life: new specialties can get to market more quickly, even while our customer relationships become deeper and more complicated; on reach, a quarter ago only a subset of Hers weight loss customers could use our AI-native experience. By the end of the quarter, the large majority of weight loss customers across both Hims and Hers have it available, and it's altering the way customers interact with their care. Customers who have the new experience are sending 4x as many messages on the platform, which helps them remain better connected to their care team and stay on track with treatment. We expect that before long, all weight loss customers will have this experience, and we'll start extending it to customers in our other specialties, such as hair, sexual health, and testosterone. On depth, AI now influences the customer journey at every point; we started out by deploying AI once a prescription had been written, taking care of routine needs and passing clinical decisions along to a provider or care coach. We keep seeing this produce a decline in non-clinical tasks that humans handle, even while daily customer touchpoints grow enormously thanks to higher engagement. We're beginning to bring those same AI capabilities into the journey sooner, before any prescription is written, which helps us grasp each customer's needs earlier and more fully. Providers notice the difference just as much as customers do. Clinicians stay in control of every clinical decision, and each AI interaction gets monitored and assessed against clinical standards. What AI alters is where provider time is spent: on judgment instead of paperwork. Our tools now produce first drafts of patient responses shaped by each patient's own chart, and a growing number of providers and care coaches use that draft as the jumping-off point for the thousands of messages they send daily. AI tools help customers finish their medical charts and keep them current, so providers spend less time collecting information and more time making clinical decisions. As these tools become more routine on our platform, customers see the results firsthand. For non-clinical questions in our AI-native experience, the typical response time is now measured in minutes instead of hours, which gives customers a genuinely always-on experience. On velocity: delivering this at scale takes world-class talent, and this quarter saw the biggest hiring push in the history of our engineering organization, with strong, efficient teams brought on both in the U.S. and abroad. Equally important, our platform approach amplifies what each of those engineers can accomplish. Platform updates are going out in less than a day, and large-scale project completions have more than doubled quarter over quarter. We are delivering more while becoming more efficient. Taken one at a time, these are incremental steps. Taken together, quarter after quarter, they transform what the platform can do for the people who rely on it. As additional customers move to the updated experience and more providers use these tools to bring their clinical judgments to patients faster, we expect care quality and depth on the platform to continue climbing. We believe customers who have that experience will ultimately remain with us longer, and that more will join us for a truly connected, comprehensive health experience. I am thankful to the talented team that makes this possible. The work is complex and the stakes are high, and that is what makes the impact on millions of people worthwhile. I look forward to sharing further progress next quarter. Back to you, Andrew.
Thank you, Mo. That approach is how we're earning the customer relationship: across every category, in every market, each day. Our view is that, over time, healthcare value will flow to whichever platform places the customer relationship above all else; that platform is what we're building; for close to ten years, we've gained the trust of nearly 3 million people — more than any other digital health company — who brought us health concerns they weren't comfortable taking anywhere else. Now they can count on us for a much fuller offering: accessible diagnostics, an AI-native care experience, industry partnerships that unlock assortment, and a steadily growing range of specialties. We have over a million square feet of our own pharmacies, labs, and supply chain, and that makes care quicker and less expensive; with top AI experts steering the platform, each customer we serve now improves the experience for the next. There are all sorts of reasons people turn to Hims & Hers. What they're finding, thanks to nine years of investment in these capabilities, is that they can count on us across their whole journey, whichever treatment ends up being right for them. That's why we're confident we can win the trust of tens of millions of customers over time. Achieving that won't come through one offering or one niche. Instead, we'll deliver scale alongside a highly personal experience, and selection is what everything else rests on. Companies that transformed daily life have always been distinguished from those that seized a moment and then lost it in exactly this way. We're creating the platform that will transform how people obtain care, and creating it demands bold yet disciplined spending. Naturally, the quarter just ended and the one coming up both count, but our focus remains on the bigger picture of where the industry is heading over time. With that said, I'll turn things over to Yemi, who will go through the financial details more thoroughly.
Thanks, Andrew. During Q3, we kept putting what we've learned into practice and made a deliberate series of choices that we're confident will set Hims & Hers up for durable growth over many years; some of these choices will likely bring volatility in the near term, but in our view they'll improve the subscriber experience across the platform and, in the end, fuel long-term revenue growth along with healthy free cash flow. There are four areas I'll go through today. First, the results for our third quarter, including the subscriber trends observed during the quarter. Second, the investments being made as we move into the new year and the reasons they leave us highly confident about the road ahead. Next, our guidance for Q4 and the entire year. And last, the approach we will apply to maintain a rigorous standard for capital allocation as we head toward 2027. Q3 revenue climbed 49% compared with a year earlier, reaching $890 million, marking our second consecutive quarter of faster revenue growth. That quarterly figure excluded $18 million related to scaling membership revenue within the weight loss offering, which is deferred and will be recognized in Q4; this deferral has no impact whatsoever on free cash flow generation. Subscribers were up 13% year over year at 2.8 million, even though they fell by 100,000 net subscribers sequentially quarter over quarter, driven by measured marketing spend in the domestic weight loss specialty and by brand migrations in our international markets. I'll get into that dynamic as we go through how the domestic and international parts of the business performed, and then turn to how growth is affecting profitability and cash flow generation. Domestic revenue growth accelerated for a second quarter in a row, reaching 21% year over year, with US operations producing $657 million of revenue, compared with 16% growth in Q2. That acceleration came about even though we held back on marketing investment during Q3. During the last six months, the shift toward weight loss that we implemented late in Q1 has been a tremendous learning experience. Working alongside Novo has shown us how to grow a new category consisting largely of branded products carrying higher price points than our traditional lineup. Introducing the Wegovy pill via that collaboration with Novo generated substantial interest and brought many new consumers to the platform, driving subscriber gains at record levels across the first half of the year. Expanding our weight loss specialty at such a fast clip has driven home a lesson we've already absorbed in our other specialties: lasting growth calls for a wide range of choices that speak to distinct consumer segments, along with tools that foster deep engagement across a subscriber's whole care journey. Since we understood that a wider weight loss assortment and a more connected care experience would be landing on the platform in Q4, we intentionally decided to hold back on marketing spend through Q3. That decision, as Andrew noted, sacrifices near-term subscriber growth in exchange for what we view as a stronger long-term position. Let me walk through each of these levers briefly and explain why we think they underpin long-term growth in the weight loss specialty. To start, we intend to widen what is available on the platform, giving consumers access to a broader range of treatments. Thanks to our agreement with Lilly, subscribers can now obtain Foundayo and Zepbound through a smoother experience. In addition, we expect our partnership with Novo to continue performing well, since we currently offer both the Wegovy pen and pill, and we plan to add CagriSema once it becomes available. Next, we aim to keep expanding the capabilities and reach of our proprietary AI platform that serves consumers. At the close of the quarter, 70% of weight loss subscribers had reached this AI-native experience, and we anticipate that nearly 100% of weight loss subscribers will reach it before the year ends. We think that if we keep scaling, providers will be able to match patients with the right treatment plans more efficiently, and patients will also get an easy way to connect with providers when different plans or dosages are needed. We expect domestic revenue to keep growing over the long term outside our weight loss specialty. Hers continues to make progress toward hitting $1 billion in revenue this year, as specialties like dermatology and menopause keep scaling alongside weight loss. Testosterone continues to make progress toward a $100 million annualized revenue run rate, and we expect that trajectory to keep strengthening with last month's launch of injectable solutions onto the platform. Turning to international, our global expansion efforts continue to thrive. Revenue grew more than 4x year over year to $233 million. That figure includes roughly $135 million from Eucalyptus, while the remainder of the international portfolio posted growth of almost 80% compared with a year earlier. During the third quarter, we began the work of bringing and broadening the Hims & Hers brands worldwide on top of Eucalyptus's platform. In Australia and Germany, the Hers brand made its debut, and within the UK we widened the range of specialties offered. The Hims brand likewise debuted in Germany and Australia, extending its worldwide footprint past the UK. Bringing our brands together is expected to produce some subscriber volatility in the near term, yet it will open up future chances to capitalize on global branding strategies and assets. On profitability, GAAP net income for the third quarter came in as a loss of $33 million. We've noted previously that expanding the platform remains our objective, though we intend to pursue that expansion while still producing robust adjusted EBITDA and free cash flow. In the third quarter, adjusted EBITDA rose 37% versus the prior quarter, reaching $82 million, which equates to a 9% adjusted EBITDA margin. Much like revenue, adjusted EBITDA excluded the $18 million in revenue deferred as of the close of the third quarter. Third-quarter gross margins came in at 57%, roughly 7 points lower than the previous quarter. The main factor behind that decrease was growth in branded weight loss products and our international business, both of which generate lower gross margins. Expanding our platform remains our number one objective, which means reaching as many consumers as we possibly can. As we grow, we'll continue using a few key levers to keep cash flow healthy. The most fundamental of these is our investment in technology talent and the platform, which equaled 8% of revenue in Q3. Our approach to building technology talent has been intentional, and it is positioned well to create leverage across several important areas. Marketing comes first. When consumers receive a best-in-class experience at every stage, retention improves. During the previous quarter we launched the Hers 2.0 app, and expanding that AI-native experience is demonstrating an early capacity to lift consumer satisfaction, which we believe will convert into stronger retention. Marketing came in at 28% of revenue, an improvement of 7 points versus the prior quarter, while revenue growth accelerated quarter over quarter. Next, we believe this team has an opportunity to create additional tools and capabilities capable of automating a greater share of our fulfillment facilities. Advances on that front enabled us to bring operations and support costs down by 1 point quarter over quarter as a percentage of revenue, to 12%.
Finally, looking out over the longer term, the engineers we have recruited are capable of building an architecture that reshapes in a fundamental way how our organization operates; our expectation is that this lets us grow G&A and support functions more slowly than revenue, yielding multi-year leverage opportunities once it takes hold. On a GAAP basis, G&A expenses in the third quarter already came down 5 points versus the prior quarter, reaching 17%. A sharp emphasis on efficiency as we scale produced $65 million of cash flow from operations along with $26 million of free cash flow during the third quarter. At the close of the third quarter, cash and investments totaled more than $710 million. That leads me to the investments we are making as we enter the new year, and why those give us confidence in the road ahead. As Andrew noted, our long-term aim is to serve as the first and primary contact worldwide for consumers' everyday health needs. A sturdy balance sheet plus solid execution will put us in a unique position to pull the growth levers required to keep turning that aim into reality: using technology to enhance the subscriber experience, expanding into new specialties, widening access to more personalized care, growing partnerships so we become a world-class curator of health services, and broadening our global footprint. Let me call out three areas where we expect to concentrate investment over the coming quarters. First, we anticipate that investment in international will be larger as the Hims & Hers brands launch across the world; early signals from AI initiatives are strong, suggesting meaningful gains to our US operating cost structure are achievable. Once those savings materialize, we expect them to free up a bigger pool of resources for reinvestment that accelerates platform expansion. While we have learned a great deal about scaling our branded weight loss category in the US, our international teams bring multiple years of experience in this area. Consequently, we expect to push aggressively into marketing strategies and strategic pricing initiatives in the UK and Germany within the weight loss specialty, and also into expanding other specialties including dermatology, sexual health, and low testosterone. In the US, we have built ecosystems designed to benefit from economies of scale and generate strong cash flow; we believe that experience puts us in a unique position to capture scale and establish the next wave of future profit generators, which we expect to include the UK and Germany. Second, we will keep investing in our technology talent and platform. This quarter saw the largest hiring volume in our engineering organization's history, and the early effect on platform enhancements is already beginning to multiply what each of our engineers can deliver; we believe this will let us bring our AI-native experience to more subscribers throughout the care journey, driving stronger engagement and retention while helping more subscribers use the platform for more comprehensive care. On top of that, this talent is essential for reshaping how we run our cost base and for driving meaningful leverage on G&A expenses as time goes on. Third, our supply chain is a vital element of our brand — consumers link it to safety and trust — and it lets us scale new specialties efficiently. Later this month, we expect to kick off the first phase of our peptide offering, which includes sermorelin, glutathione, and NAD+. We intend to add BPC-157 and TB-500 once the regulatory environment allows. Our multi-year investment in our US-based peptide manufacturing facility and our fulfillment facilities makes it possible for us to produce and compound key peptides here at home, which we believe sets us apart from other offerings currently in or likely to enter the market. Putting money into our supply chain also lets us widen the assortment of offerings on the platform, much like the launch of injectable testosterone last month, and capture efficiencies as we verticalize more offerings over time; with that background, I'll now take you through our outlook for the rest of the year. For the fourth quarter, we anticipate revenue between $875 million and $895 million, which represents a year-over-year increase of roughly 42% to 45%. We expect adjusted EBITDA to land between $70 million and $90 million, which works out to an adjusted EBITDA margin of 9% at the midpoint of both ranges. For the full year, we are narrowing our 2026 revenue outlook to $3.13 billion to $3.15 billion, representing a year-over-year increase of 33% to 34%. We are lowering our 2026 adjusted EBITDA guidance range to between $257 million and $277 million. This reflects the more aggressive strategic pricing and marketing actions we expect to take in the UK and Germany, along with the weight loss membership deferral mentioned earlier. The adjusted EBITDA and revenue ranges imply an adjusted EBITDA margin of 9% at the midpoint of both ranges. To help put our outlook in context, I'll highlight a few key points. First, we expect the impact of deferred revenue from accelerating membership revenue in our weight loss and newer specialties to hurt revenue and adjusted EBITDA by at least $20 million for the full year, since certain membership payments received in December will not be recognized as revenue until January. Second, we expect to invest in delivering additional value through pricing changes in our weight loss specialty and in heavy marketing investment to scale the Hims & Hers brands in strategic markets such as the UK and Germany ahead of the period of historically higher acquisition levels in the first quarter. While this will affect near-term revenue, we believe that efficiencies from economies of scale and subscriber gains will make these moves accretive in the mid-term. Our expectation is that our international business delivers at least $650 million of revenue in 2026, up from our prior expectation of $600 million. Third, within our weight loss specialty in the US, we expect to keep moderating domestic marketing investment in the fourth quarter, and that could mean one more quarter of headwinds for subscriber count. In the fourth quarter, our focus will be on broadening the weight loss assortment on our platform, including Foundayo and Zepbound. As we head into the new year, we're excited to offer customers an assortment from both Lilly and Novo, and we believe this will create real opportunities to strengthen our weight loss business. Fourth, revenue contribution from our peptide offering is not expected to be material in the fourth quarter. We'll take a similar approach of gated investments to scale this offering, and we'll also closely monitor the regulatory landscape to inform the overall breadth of the offering. Fifth, we expect gross margin declines to begin to moderate as the pace of mix shifts toward international and our weight loss specialty starts to moderate. Continued gains in our operating cost structure from our technology investments lay a foundation for further reinvestment in new specialty and international expansion, as well as future margin expansion. Lastly, we expect to drive positive free cash flow for the full year of 2026 and to be well-positioned to do the same in 2027. The strategic pivot we made in the first quarter has transformed the business, and it will position us well in the long term.
As Andrew mentioned, at present we are investing in order to achieve our long-term aim of becoming the leading global destination for consumers' health and wellness requirements. The capital we direct toward that aim will likely produce some variability between quarters, but it leaves us in a strong position for the future, similar to investments we've made previously. Determining how to grow our branded weight loss specialty will be extremely important over time, because we expect rapid innovation in that area throughout the next few years. We think generic products arriving later in the specialty will complement the branded ones, opening the door for us to serve an even wider population and to gain from solid unit economics through verticalized operations; we've witnessed this in the US across other specialties like sexual health and hair, in both scale and economics; we're now seeing early signals of that same pattern in our weight loss specialty in Canada, where generic options launched earlier this year. Average monthly orders have climbed more than 50% after generics launched, and margins are gaining as well from a mix shift toward those cheaper options. In the specialty areas where we've been active for a longer period, that same transition expanded the market we can serve, improved retention, and delivered substantial margin growth as time went on. Canada gives us an early look at how we expect weight loss to evolve. Before I hand things over to Bill, I'll close with the framework we believe will allow us to maintain a demanding standard for capital allocation as we head toward 2027. Even as we make long-term investments, we assess them continuously through a thorough scorecard. We plan to explore our longer-term success metrics in greater detail next quarter together with our 2027 outlook. Broadly speaking, we gauge our investments by how effectively they meet our long-term company goals. Those goals are: first, increasing subscriber numbers and advancing toward holistic care—tracked through subscriber count, retention, and how many subscribers receive treatment for two or more conditions on the platform; second, broadening the range of partnerships with other healthcare participants on our platform; third, lowering our overall operating cost structure, which we track as leverage on costs expressed as a percentage of revenue; fourth, deepening our category leadership in the countries where we operate, tracked by how many countries we rank number one or number two in; fifth, scaling new specialties and the breadth of assortment on our platform efficiently; and finally, generating robust free cash flow. We’re eager to keep you informed about how our investments and initiatives are advancing in each of these areas going forward. None of what we achieve would be possible without the tremendous work done by Hims & Hers team members across the globe. I’d like to thank them, along with our subscribers and shareholders, for supporting our goal of helping the world feel great through the power of better health. With that said, I’ll now return the call to Bill so he can start the Q&A with two questions from our retail community.
Thanks, Yemi, and I appreciate everyone who submitted questions over the weekend. The first one concerns the changing wearable market and comes from the Hims House community. A number of top wearable firms today provide blood panels within their apps, the ability to import health records, and access to clinicians on demand. Meanwhile, we've noticed industry thought leaders making the case that once collecting health data turns into a commodity, value will migrate toward whoever controls the action layer — that is, the moment an insight becomes either a treatment plan or an interaction with a clinician. Hims has discussed integrating wearables and uploading health data from outside sources. Could you bring us up to date on your plans in this area, and on whether you'll partner with wearable companies or build your own devices, and what customers will receive from the Hims experience that differs from what those other apps give them?
Thanks, Bill, and thanks Hims House for that question. Broadly speaking, I completely agree that as these devices become more widespread — which is a wonderful development for empowering consumers and helping them understand their health — the value will really end up accruing to the actual clinical layer and then the care management layer, since ultimately I believe that device data combined with healthcare practitioners making sound decisions about your health is where the value truly lies. I think wearable data generally is a crucial component of examining a person's whole health, so from our standpoint the plan is to be universal in enabling integration of all these wearable devices into the platform, so that providers and patients can bring that data into the ecosystem regardless of preference, right? Some men might prefer a particular form factor, women another, and obviously there are emerging devices, such as what Google launched recently, that are lowering the price and making these even more accessible. Broadly, in addition to that broad allowance of integration, I also simply believe these devices remain too expensive and that ultimately the patient should own the data, which shouldn't be restricted by a subscription. As a strategy for us, I also think part of this eventually is to offer our own devices to Hims & Hers patients as part of membership dynamics at near cost, with really no data subscription lock-ins. The purpose here is really to broaden this type of monitoring to the masses, and ultimately I believe this type of integration will drive a much higher degree of overall engagement, much stronger retention, better clinical outcomes, and ultimately drive value for the platform and for consumers in mass who currently lack access to these types of devices.
Thanks, Andrew. Our next question concerns the expanding peptide opportunity, and it comes from Andrew T. From recent hiring, it looks like Hims keeps developing the capabilities and expertise needed to add peptides to the platform. In the end, how much of the peptide manufacturing process do you plan to handle internally, and how much will stay with partners, and what is the anticipated timeline for commercial production? Have you picked up any early demand signals from the waitlist you recently launched? On the membership side, do you expect customers to pay an extra fee for peptides, or is there a chance to bundle them with existing specialties such as weight loss or hormone therapies?
Thanks for that, Andrew. The waitlist we rolled out not long ago has generated an enormous amount of buzz, and as Yemi mentioned in the prepared remarks, the Peptides Plus category will be launching at the end of this month, and it covers items such as glutathione, NAD, sermorelin, and B12, and then further therapies for the new peptides such as 157 and 500 will be added to the platform once regulators permit them. This has required a substantial commitment from us. As most of you know, we bought and have since integrated a peptide manufacturing facility located in Menlo Park. For certain of the newer peptides where the supply chains for the raw active ingredients, such as TB-500 and 157, aren't really at the quality level we would want to see, we will produce the raw APIs at our Menlo Park facilities, which I believe actually makes us really the only US company able to provide that level of quality oversight for these therapies, and I think that's extremely important. The team, led by Dr. Anand, our Hims Chief Medical Officer, has been actively putting the guardrails, the clinical standards, and the lab testing in place for this, along with partnership and guidance from Dr. Andrew Huberman, whom we announced today has joined the board of directors. On the membership side, I think that was also a great question. We're going to launch this offering with a membership structure that, over time, really incentivizes and enables more whole-life care, and that means multiple treatments across multiple therapies, letting you address different aspects of your health with incentivized pricing, so it's simply easier, more affordable, and more flexible for you as an individual. You should expect this membership to enable cross-category expansion in a really seamless way, and in a more cost-effective manner, across categories such as hormonal health, peptides, hair, sex, and eventually weight as well.
Thanks — having said that, I'll hand things over to the operator, and then we'll kick off the customary Q&A.
Good afternoon, and thanks for taking my questions. I just wanted to ask about near-term subscriber dynamics, particularly since revenue growth is speeding up. How much of the subscriber decline comes from lower acquisition spending versus possible shifts in retention? And how should we think about subscriber growth over the next quarter or two? Then I have a quick follow-up.
Thanks for the question, Maria. As for the subscriber trends in the third quarter, and we alluded to some of what we expect in the fourth quarter, a meaningful portion of that is tied to the deliberate decision to hold back on investment into the specialty. Andrew covered this in the prepared remarks, but to restate our position: we're going all in on widening the assortment during Q4 through the new Lilly partnership, bringing in Foundayo and Zepbound, plus CagriSema as soon as it's available. That gives us a fuller lineup and a more complete, holistic experience overall. We anticipate having it in place by Q1, which has historically ranked among the seasonally strongest quarters for acquisition. Once we reach that point, we'll ramp the marketing engines back up, and we'd expect subscriber growth to bounce back and expand from there.
Understood — that helps a lot. So now that Lilly is on the platform alongside Novo, how much of the opportunity comes from bringing in incremental or new members versus possibly shifting demand between the two? How should we think about you now offering solutions from both Lilly and Novo, and that driving stronger customer acquisition and retention?
Thanks, Maria — great question. From what we've observed in other categories over time, breadth of assortment is ultimately the true path to unlocking category growth. Many different customers enter through the metabolic health category with widely varying goals, concerns and sensitivities, and widely varying preferences when it comes to form factor, dosing, and the trade-off between side effects and weight loss. Integrating Lilly's therapies into the category, I think, will do wonders for the category as a whole, and I believe it will ultimately lift total volume in mass across all partners. That, to Yemi's point, was a major driver behind this deliberate pullback in marketing — namely, there are well-established aspects of this weight category we could improve: by driving assortment through this new partnership with Lilly; through really deep collaboration over the last month and in the months ahead with Novo on different starter packs and pricing offerings that help patients succeed more with their therapies; through preparation for new therapies coming down the line such as CagriSema; and then also by introducing technical capabilities in this new category with multi-month subscriptions and flexible plans, which, as has been such a hallmark of all other categories on the platform, give patients more flexibility, better pricing lock-in, and ultimately better commitments. These are well-established things that have worked across categories. Our perspective, I think, is that ahead of Jan 1, when we know this category really explodes with demand, let's unlock those levers, let's focus there, let's not needlessly burn that cash, and prepare to do this the right way 45 days from now.
Hello, and thank you for taking my questions. Perhaps we could dig into the choice to somewhat reduce marketing spending: did you observe a diminished return on each extra marketing dollar for some reason over this stretch, or might this have been a step taken ahead of the Lilly deal being signed so that marketing would be spread more evenly across several partners going forward? Could you expand on that a bit? And when you consider the return on those additional investments as we look toward further product expansion, what is your expectation regarding the timeline for actually realizing the benefit from that spending once marketing ramps back up at the start of the year? Thank you.
Yemi, perhaps I'll handle the first portion and you can handle the second; as all of you observed over the last quarter or two, the business underwent an enormous transformation, shifting from the compounding offerings to the partnership with Novo, and the Wegovy offerings on that platform, including the Wegovy pill, experienced truly remarkable acceleration, and customer demand for that therapy is enormous and remains enormous. What we've noticed over just the past few months as we've examined those customers closely is that there are very obvious chances to position them better for success: chances to give them subscription features that secure improved pricing as they reach titration levels where weight-loss benefits appear, improved early starter offerings that let them obtain the advantages of higher doses at improved pricing, and finally we've seen this consistently where many patients arrive asking specifically for Lilly products like Zepbound vials. Given all of that, I think, as we considered the category, there was a genuine chance to pause briefly and prepare things properly for January and ensure that is accomplished the right way, rather than attempting to direct the team toward the essential difficulties of scaling so rapidly. Directing that same team toward establishing the structural chances for customers to be served better, we believed, was a far superior use of that resource, particularly considering the patterns we've historically witnessed in January, when that demand accelerates sharply into Q1.
I guess the thing I'd tack on there, Ryan, is that this is a movie we've watched before. When you bring in new capabilities such as duration, along with wider breadth when it comes to pricing options and assortment, a couple of things have typically happened across the specialties we've been in for a while. We usually do see better retention, since you can steer consumers toward different products or duration levels. We've also historically watched acquisition improve, whether that shows up as lower CACs or more consumers finding the platform organically. As Andrew said, we're actively leaning into growing those capabilities on the platform through Q4 so we're effectively ready to go once the January seasonal high, or seasonal peak period, kicks off. We'd expect to begin capturing some of those benefits in Q1, and then for pieces like retention, those would cascade across the year throughout 2027. That's a playbook we've witnessed across every one of our historical specialties.
That's helpful. So maybe just to follow up, a question seeking clarification about the peptide opportunity. You said regarding TB-500 and BPC-157 that once it's permitted from a regulatory standpoint, you'd want to make those available on the platform, so to speak. Could you discuss what additional factors you're watching for on the regulatory front, now that HHS has put out that proposal regarding enforcement discretion for the six peptides recommended by the PCAC? What incrementally are you looking for beyond that enforcement discretion? Thanks.
Great question. I'll probably mangle the exact terminology, but basically at this moment we're in a comment period, and the FDA has issued the proposed ruling that came from HHS. We anticipate that within the next couple of weeks those comments will be gathered together, and then a perspective from FDA on the explicit rulemaking will come about; along with that come all sorts of decisions concerning the necessity of API testing, which tests they'll be seeking, and the standards they'll expect from various facilities. I think once all of that is finalized over the coming weeks, we'll have far more clarity regarding what the final regulatory rulemaking decision truly looks like.
That is a really good question. Perhaps I'll say a bit about what the consumer experience looks like, and then Yemi, you can address parts of the operational picture. Our investment here is happening in a truly thrilling way; this quarter set the record for the most engineering hires added in any quarter in the company's history, and a very large share of that went into our AI team, which is delivering quite tangible results for patients. The 2.0 Hers app, which has genuinely pushed the AI coach to the center of the conversation, has increased actual patient engagement by more than 4x, so it is simply fueling far richer interactions, surfacing side effect concerns sooner, bringing forward titration questions, dosing adjustments, and documentation of outcomes; we're genuinely thrilled to see engagement at that level, since ultimately it carries downstream effects for getting patients onto the right therapies faster and, in the end, achieving far better outcomes. Beyond that, I think the capacity to help shift the conversation away from one in which you are handing off between six or so different people — say, from a pharmacist to a nurse to a care coach to a doctor — and to genuinely begin developing what this AI care coach can do so that every one of those people in the threaded conversation gains greater leverage on speed and quality, strikes me as an enormous unlock. Today, inside our EMR, for instance, providers are receiving pre-written notes sent back to patients that account for all of their sensitivities, all of their charts, and all of their existing medications, which lets those providers respond to patients at much higher quality. It is alerting various care coaches about sensitivities, it is raising side effect concerns far more quickly, and then it ranks those for the providers so they can spend their time delivering high-quality care to the patients who most need it, in priority order, rather than on note-taking, documentation, and administrative work, which so often consumes so much of their job. We believe this will ultimately have an enormous effect on engagement, outcomes, retention, and the quality of experience in both provider and patient relations.
And to build on that, Justin, I believe, as Andrew said, the emphasis really is on experience quality, which will surface through metrics like retention and how easily we acquire customers. I think as we also concentrate on things such as assisting providers in identifying and prioritizing how patients should be treated, along with some other elements Andrew brought up, one result of that is simply greater overall efficiency inside the platform as well — truly routing the most impactful or complicated cases to the right individuals, and then figuring out the most efficient ways to solve some of the simpler elements. I think we're already beginning to see signs of success there that we are certain will keep propagating across the platform. I think, as we also mentioned during the prepared remarks, there's the ability to begin leveraging some of this technology inside our fulfillment centers as well, to start unlocking additional efficiency gains there. Really, some of that simply comes with the overall scale that we see, paired with growing technology capabilities that we're confident will let us keep unlocking efficiency gains in the near term.
Yeah, thanks. Turning to the international side, you mentioned $50 million of upside to sales versus the prior guidance — could you just speak to which specific products are fueling that, and also give us some context by geography?
Thanks for asking. Oh, sorry — go ahead, Andrew.
I'll get us started. I think broadly speaking, what we're observing is a great deal of learning that carries across markets. Here in the US on the weight loss front, we've benefited enormously from insights gained in our international markets, which are roughly 18 to 24 months ahead when it comes to engaging with the branded medications and working out the flexibility of how to launch those at the right pricing and with the right packages, and so on. Conversely, the success in the US market — with genuinely diversified growth engines and differing diversity in customer adoption across therapeutic categories — lets us carry that same strategy abroad into core markets such as the UK, Germany, and Australia, where we hold either the number one or number two position and are working to capture massive share gains. What you'll see over the next couple of quarters is a consolidation of the Hims & Hers brands in those key markets, along with bringing the existing US categories that have generated incredible demand and scale — across hair and dermatology and sexual health, hormonal balance, et cetera — into each of those Hims & Hers brands. It isn't any single category or product line, Craig. I think really it's just the expansion of the brands within each of those markets, evolving from what was historically Juniper's weight-loss-centric brand into something diversified across Hims & Hers and now expansive across three to five different categories.
Understood. So I just have one more question, this one for Yemi, about gross margin — I know there's a mix effect from weight loss and from international. Could you give us some context on which of those is likely the larger drag in the near term, and then over the longer term, are there levers in the model you can pull to push gross margin back up somewhat?
Thanks for that, Craig. On the quarter-on-quarter dynamics, I'd say a big portion of it came from international. Last quarter, I believe you didn't yet have the full impact of Eucalyptus showing up in the results. Now in Q3, you effectively have three months in the quarter, so where the international impact is concerned, this would rank among the heavier quarters we'd anticipate on that front. On the gross margin question, I think we'll return to that shortly. Right now, effectively, the focus is on how we leverage the platform to drive scale while also making sure we're generating strong free cash flow, with EBITDA dollars serving as a proxy for that. While there are gross margin dynamics and some volatility in the GAAP financials that we've discussed previously, stepping back, this ranks as our second or third highest quarter of adjusted EBITDA dollars brought onto the platform. With that remaining the focus, we're confident we have several levers we can effectively pull; that said, on international, there are opportunities, as Andrew mentioned, as we diversify the platform by scaling additional categories such as sexual health, dermatology, and low testosterone overseas and kind of run the US playbook, similar to what we saw in the US over the mid to long term, you'd expect gross margin expansion to begin showing there; that said, much of the focus is on the principles of scaling the platform, but doing so in a way that drives strong economies of scale and EBITDA dollars.
Thank you. Both of you touched on a few of the lessons you've drawn from the EU, and in particular the remark about economics improving over time, which I think we've grown accustomed to seeing in the US before weight loss. It sounds like what you're observing in the EU is comparable, so I'd ask what needs to hold true, or what happens in the market that lets you grow gross profit? Is the premise here that you're seeing substantial growth in the number of patients adopting, or that gross margin per script can stay steady as well?
Thanks for the question, Eric. Broadly speaking, what we've observed — and we've observed it both internationally and, as you point out, domestically in categories such as sexual health and hair — is that over time, as new offerings enter the market — in Canada, for instance, which runs 24 to 36 months ahead of the US when it comes to new category entrants, you now have generic therapies live in Canada — you see fairly substantial competitive offerings expand, and then you see pricing decline through that competition; that pricing, even if it's somewhat marginal, ultimately drives far broader uptake among consumers and much higher lock-in from a duration standpoint, because the ability to pay and the willingness to pay are much greater. That ultimately drives much better customer adoption dynamics and retention profiles, and from there, as you verticalize all of these elements — some of which are the generic and some of which are simply competitive offerings pushing price down — you see flow-through to meaningfully better margins on a per-script basis. This is essentially the very same thing that occurred in sexual health and the hair category: as assortment came to market, as prices fell, as generics were introduced, you were able to have both a great range of therapies and verticalized offerings that in total make a really healthy category; we're investing in the weight loss category domestically with, I think, very clear eyes as to where this lands from a profitability standpoint, and I think that's why in this quarter there was a willingness to simply spend the time on the things that are known-knowns, which will unlock much better engagement from patients and much better outcomes, but also our willingness to scale that category in the next few years domestically with an eye toward what is happening as new therapies come to market, of which there are nearly a dozen in Phase 2 and Phase 3, and then also what happens as that generic comes out, which has a very clear line of sight in both the US and the EU markets.
That brings us to the close of the question-and-answer portion. Today's call ends here. We appreciate your participation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Hims & Hers Health, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Hims & Hers Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.